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2

MELAMPOMAGNOLIDE B DERIVATIVES AS
ANTILEUKEMIC AND CYTOTOXIC AGENTS

-continued
HOZC

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the bene?t of US. provisional
application Ser. No. 61/405,978 ?led on Oct. 22, 2010, the
entire contents of which are incorporated herein by reference.

O

I COZH,

Dimethylaminoparthenolide (DMAPT) furnarate; LC—l

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under

grant number W81XWH-07-1-0601, awarded by the United
States Department of Defense; and under grant number
C024964, awarded by the New York State Stem Cell Foun
dation. The government has certain rights in the invention.

20

Melampomagnolide B (MMB)

BACKGROUND OF THE INVENTION

1. Field of the Invention

25

5, 1147. In particular, parthenolide causes cell death in AML
stem and progenitor cells in vitro, with minimal toxicity

Melampomagnolide B (3) is disclosed as a new antileuke

mic sesquiterpene. A biotin-conjugated derivative (4) of
melampomagnolide B was prepared to elucidate its mecha
nism of action. A study of the biochemical interactions of the

Parthenolide induces robust apoptosis of primary acute
myeloid leukemic (AML) cells. Guzman et al., Blood, 2005,
105, 4163; Guzman and Jordan, Exp. Opin. Biol. Ther., 2005,

30

towards normal hematopoietic cells. The apoptosis induced
by parthenolide is not solely due to NF-kappaB inhibition, but

biotin probe suggests that melampomagnolide B derives its

rather arises from a broad set of biological responses, which

remarkable selectivity for leukemic cells over normal

likely include activation of p53 and an increase in reactive

hematopoietic cells from its unique ability to exploit bio

oxygen species. Parthenolide has also been the source of
several novel antileukemic compounds arising from our pro

chemical differences between the two cell types. Prodrugs of
Melampomagnolide B are disclosed.

35

2. Description of the Related Art
The past several years have seen a surge of interest in the

anticancer properties of sesquiterpene lactones. A germacre
nolide, parthenolide (PTL, 1) has been noted for its remark

Chem. LeZZ., 2009, 19, 4346; Nasim and Crooks, Bioorg. Med.
40

dimethylamine-adduct of parthenolide (DMAPT, LC-1, 2),
45

anti-apoptotic genes under NF-kB control. Bork et al. FEBS

Len. 1997, 402, 85; Wen, J. Biol. Chem, 2002, 277, 38954;
Hehner et al., J. Biol. Chem. 1998, 273, 1288; Sweeney et al.,
Clin. Cancer Res., 2004, 10, 5501 ;Yip-Schneider et al., Mol.
Cancer. Then, 2005, 4, 587; Nozaki et al., Oncogene, 2001,

Chem. Lell., 2008, 18, 3870. Such adducts showed retention

of antileukemic properties of parthenolide; in particular, the

able antileukemic properties. Skalska et al. PLoS ONE, 2009,
4, e81 15. Initial efforts pertaining to the biomechanistic study
of parthenolide and its analogs revealed that they seem to

promote apoptosis by inhibiting the activity of the NF-kB
transcription factor complex, and thereby down-regulating

gram over the past decade. For example, parthenolide analogs
were prepared by adding amines to the exocyclic ole?n of the
enone function of 1, thereby rendering the resulting com
pounds water-soluble. Neelakantan et al., Bioorg. Med.

50

which has progressed to phase-I clinical trials in the United
Kingdom for the treatment of AML, ALL and CLL. Neela
kantan et al., 2009.
Unfortunately, DMAPT has a relatively short in vivo half
life (approximately two hours) which may limit its activity.
Moreover, the design of this molecule does not readily afford

opportunities to develop tissue-targeting strategies due to
stability problems associated with drug formulation. This is
related to the ability of the drug to undergo reverse Michael
deamination reactions to generate parthenolide. Thus, there is
a need to both improve the biological activity of PTL and

20, 2178. Nuclear factor kB (NF-kB) is a transcriptional
regulator that plays a central part in responses to in?amma

tory signaling.

create novel pharmacological agents with drug-like charac
55

teristics that can be formulated as oral dosage forms.

One PTL analog that was synthesized via selenium oxide
oxidation was a C10 hydroxymethyl derivative. Notably,

60

hydroxylation of the C10 methyl group of PTL resulted in the
concomitant conversion of the geometry of the C9-C10
double bond from trans to cis. The resulting product, a

hydroxymethyl 1(10)-cis-parthenolide analog, has previ
ously been reported as melampomagnolide B (MMB).
Melampomagnolide B (MMB, 3) is a melampolide originally
65

Parthenolide (PTL)

isolated from Magnolia grandi?ora. El-Feraly, Phylochem
islry, 1984, 23, (10); 2372-2374.
It is herein disclosed that melampomagnolide B (MMB, 3)
has been identi?ed as a new antileukemic sesquiterpene with

US 8,884,027 B2
3
properties similar to parthenolide (PTL, 1). Further, as a
functionalized analog of PTL, the MMB molecule allows the

synthesis of conjugated analogs that retainbiological activity.
SUMMARY OF THE INVENTION
Melampomagnolide B is disclosed as a neW antileukemic

sesquiterpene. A biotin-conjugated derivative of melampo
magnolide B was prepared to elucidate its mechanism of
action. Prodrugs of Melampomagnolide B are disclosed.

In one aspect, R is iC(O)(CR3R4)nX. In another aspect, X

is NR5R6, ORl, or SR1.

The disclosure provides a compound of the formula (I):

In speci?c aspects, R is selected from

O

NH;
20

Gly
2

0

wherein: R is selected from iP(O)(OR1)(OR2); 4CH20P

(O)(OR1)(OR2);

iC(O)(CR3R4)nX;

25

iCH20C(O)

(CR3R4)n X; iC(O)O(CR3R4)nX or %(O)(CH2)MC(O)
NH(CR3 , R4)nX; R1, R2 are independently selected from H; a

pharmaceutically acceptable cation; or optionally substituted

C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl,

3
30

O

cycloalkyl, aryl; R3, R4 are independently selected from H,
NH;

NR5R6, ORl, SR1, S(O)Rl, SOle, or optionally substituted
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl,
cycloalkyl, aryl; R5, R6 are independently selected from H; or

35

optionally substituted C1-C12alkyl, alkenyl, alkynyl, hetero

[5—Ala.
4

cycloalkyl, heteroaryl, cycloalkyl, aryl; 4C02C1-C12alkyl,
CO2alkenyl,
COZalkynyl,
COzheterocycloalkyl,
COzheteroaryl, COchcloalkyl, COZaryl; C1-C12alkylamino
or R5 and R6 optionally together With the nitrogen atom form
an optionally substituted 5-12 membered ring, said ring

40

optionally comprising 1 or more heteroatoms; X is selected

from H, NR5R6, NC(O)R1; NC(O)OR1; ORl, SR1, halo, tri
?uoromethyl, or optionally substituted C1-C12alkyl, alkenyl,
alkynyl, heterocycloalkyl, heteroaryl, cycloalkyl, aryl; n is

45

5

0-12; m is l-2; or a pharmaceutically acceptable salt, ester or

prodrug thereof.
In one aspect, R is selected from iP(O)(OR')(OR2) or

iCH2OP(O)(ORl)(OR2). In another aspect, R1, R2 are inde
pendently selected from H, Na, or optionally substituted
C l-C6 alkyl. In certain speci?c aspects, R is

50

6
20

||

55

2m+

P

|\O_

O.

20
21

60

o

65

7
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5

In a speci?c aspect, R is selected from

-continued

H
N

M WNHZ
O

O
22n:l
23n:2

§
O

WN

O
24n:l
25n:2

20

§

25

O

WN

O
26n:l
27n:2

30

In another aspect, R is 4CH20C(O)(CR3R4)MX, and X is
NR5R6. In a speci?c aspect R is

§

35

O

O

ll

EAOIVNHZ

28n:l
29n:2

40

O
H

N
O

1
-

WN/W
K/O

(i

\/

/

/

N

Of

O

0

O

302—pyr
313—pyr
or 324—pyr.

50

In one aspect, R5 and R6 together With N form an optionally
substituted ring. In one speci?c aspect, the ring is a monocy

$0M NHZ.

clic, bicyclic or tricyclic alkyl or aryl ring system, said ring
system optionally substituted and optionally comprising one
55 or more heteroatoms or a group selected from 4COi,

In another aspect, R is 4C(O)O(CR3R4)MX, Wherein X is
NR5R6. In a speci?c aspect, R is

iSOi, iSOzi, and iPOi. In another speci?c aspect,
R1 and R2 are i(CH2)aiYi(CH2)bi; Where Y is a het
eroatom or a group selected from iCOi, iSOi,
60

iSOZi and iPOi; a is an integer 0 to 5; b is an integer 0
to 5; the sum of a and b being 0 to 5; and together With N form
an optionally substituted ring, said ring optionally fused to a
cycloalkyl or aryl group to form a bicyclic or tricyclic ring

system, said system optionally substituted and optionally
comprising one or more heteroatoms.
65

In another aspect, R is or 4C(O)(CH2)MC(O)NH(CR3R4)

"X, Wherein X is NR5R6.

In another aspect, Wherein X is NRSR6 the compound a

pharmaceutically acceptable salt selected from hydrochlo
ride, maleate, fumarate, or mesylate.

US 8,884,027 B2
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7
In another aspect, the disclosure provides a compound
selected from

In certain aspects, the disclosure provides a compound of

formula (I):
(I)

wherein R is a group that is cleaved to a hydroxy group under
physiological conditions during or after administration to a

mammalian patient, thereby yielding Melampomagnolide B;
wherein R is selected from iP(O)(OR1)(OR2); iCHZOP
20

(O)(OR1)(OR2);

iC(O)(CR3R4)nX;

iCHZOC(O)

(CR3R4)n X; iC(O)O(CR3R4)nX or iC(O)(CH2)mC(O)
NH(CR3R4)nX; R1, R2 are independently selected from H; a
pharmaceutically acceptable cation; or optionally substituted
25

C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl,
cycloalkyl, aryl; R3, R4 are independently selected from H,

NR5R6, ORl, SR1, S(O)Rl, SOle, or optionally substituted
C1-C12alkyl, alkenyl, alkynyl, heterocycloalkyl, heteroaryl,
cycloalkyl, aryl; R5 , R6 are independently selected from H; or

NHFmo 0
of

30

optionally substituted C1-C12alkyl, alkenyl, alkynyl, hetero

cycloalkyl, heteroaryl, cycloalkyl, aryl; 4COZC1-Cl 2alkyl,

COZalkenyl,

COZalkynyl,

COZheterocycloalkyl,

COzheteroaryl, COchcloalkyl, COZaryl; C1-C12alkylamino
35

or R5 and R6 optionally together with the nitrogen atom form
an optionally substituted 5-12 membered ring, said ring
optionally comprising 1 or more heteroatoms; X is selected

from H, NR5R6, OR % SR % halo, tri?uoromethyl, or option

ally substituted C1-C12alkyl, alkenyl, alkynyl, heterocy
40

cloalkyl, heteroaryl, cycloalkyl, aryl; n is 0-6; m is 1-2; or
a pharmaceutically acceptable salt, ester or prodrug thereof.
In another embodiment, the disclosure provides a method
of drug delivery comprising administering to a mammal, an
amount of a compound of formula (I):

45

(I)

In one embodiment, the disclosure provides a pharmaceu
tical composition comprising a compound of formula (I) or a

pharmaceutically acceptable salt thereof; in combination
with a pharmaceutically effective diluent or carrier.

50

In another embodiment, the disclosure provides a method

of inhibiting cancer cell growth, comprising administering to
a mammal a?licted with cancer, an amount of a compound of

formula (I) effective to inhibit the growth of said cancer cells.
In one aspect, the disclosure provides a method of inhibiting
cancer cell growth comprising contacting said cancer cell in

55

vitro or in vivo with an amount of a compound of formula (I)
effective to inhibit the growth of said cancer cell.

wherein R is a group that is cleaved to a hydroxy group under
physiological conditions during or after administration to a

mammalian patient, thereby yielding Melampomagnolide B;

In another aspect, the disclosure provides a method of

treating an aberrant in?ammatory condition, comprising

wherein the substituents are as described above.

administering to a mammal in need thereof, an amount of a

In another embodiment, the disclosure provides a method
of treating bone marrow in human bone marrow transplant

compound of formula (I) effective to reduce, prevent or con
trol said condition. In one aspect, the aberrant in?ammatory
condition is an autoimmune disorder, said method compris
ing administering to a mammal an amount of a compound of

formula (I) effective to reduce, prevent or control said autoim
mune disorder.

treatment of leukemia, the method comprising treating bone
65

marrow with a compound of claim 1 prior to reintroduction of
bone marrow to patient. In another embodiment, the disclo
sure provides a method of treating a patient having chronic or
acute myeloid leukemia (CML/AML) or acute lymphoblastic

US 8,884,027 B2
9

10

leukemia (ALL), comprising administering to the patient, an

?uorescent proteins allows cells to be tracked during manipu

effective amount of a compound of formula (I).
In a further embodiment, the disclosure provides a method
of treating a patient having chronic or acute myeloid leukemia
(CML/AML) or acute lymphoblastic leukemia (ALL), com
prising administering to the patient, an effective amount of

lation. Primary AML cells exposed to a concentrated lentivi
rus encoding GFP for 6 hours. Analysis 8 hours later (A) and

at 7 days (B) post-infection. Primary AML specimens (C)
were infected with lentivirus encoding GFP and analyzed

after overnight culture. (D) Western blot showing ef?cacy of

melampomagnolide B.
prising administering to the patient, an effective amount of a

lentiviral expression of shRNA targeted to the Nrf2 mRNA.
FIG. 8 shows derivatives of MMB. Various ester, ether,
carbamate, carbonate and phosphate MMB derivatives are
proposed to act as water-soluble, orally bioavailable MMB

compound of formula (I).

prodrugs.

In another embodiment, the disclosure provides a method
of inhibiting angiogenesis in a patient in need thereof, com

FIG. 9A shows conversion of prodrug-to-parent drug

In another embodiment the disclosure provides a method

of inhibiting angiogenesis in a patient in need thereof, com

involves a chemical cleavage at the self-cleavable spacer

prising administering to the patient, an effective amount of a

through a intramolecular cyclization-elimination reaction via
imide formation under physiological conditions.
FIG. 9B shows synthesis of prodrugs 1-13 from FIG. 8.
Prodrugs l -10 can be synthesized by Steglich esteri?cation of
MMB with an appropriate amino group protected AA to

compound of melampomagnolide B
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a route of synthesis of melampomagnolide B

(MMB, 3) from parthenolide (PTL, l), and conjugation of

afford compound 34, followed by deprotection of the amino
20

biotin to 3.

FIG. 2 shows viability of primary AML specimens when
treated for 18 hours with either PTL, l, or MMB, 3, compared
to control, untreated cells.
FIG. 3 shows biological activities of 4 compared to l and 3.
FIG. 3A shows immunoblot of phosphorylatedp65 subunit of
the NF-kB complex and actin. FIGS. 3B-D shows viability of
primary leukemia cells after overnight culture at varying con
centrations.
FIG. 4 shows binding of targets of 4 in NBM and AML

samples in an immunoblot analysis using a streptavidin
probe. The asterisk* marks a non- speci?c band recognized by
SA-HRP probe. Whole cell lysates from normal bone marrow
(NBM) in lane 2 is shown in comparison to acute myeloid
leukemia (AML) cells in lane 3. An identical protein/com
pound 4 ratio was used for NBM and AML preparations.
FIG. 5 shows Western blot of primary leukemia cells that
were pretreated for 2 h with compound 1 (lanes 2, 5) or biotin
control (b.c.) (lanes 3,6), prior to a 4 h incubation with com
pound 4. Cells were then lysed and immuno-precipitated by

group. Reaction of MMB with an appropriate Boc-AA chlo

romethyl ester 35 will afford compound 36, which upon
deprotection will furnish prodrugs 11-13.
FIG. 10 A shows synthesis ofprodrugs 14-19 from FIG. 8.
Carbamate prodrugs 14-17 and carbonate prodrugs l8 and 19
25

can be prepared from the substitution reaction between

mono-Boc protected diamine or N-Boc aminopropanol (38)

and 4-nitrophenyl MMB carbonate (37), followed by depro
30

tection. Compound 37 can be prepared by reacting MMB
with 4-phenyl chloroformate.
FIG. 10B shows synthesis ofprodrugs 20 and 21 from FIG.
8. Phosphate prodrug 20 can be synthesized by standard

conditions using the phosphoramidite method. Deprotection
35

of the phosphate triester (39) can be accomplished by treat
ment with TMSBr. The oxymethyl phosphate prodrug 21 can
be synthesized by initial formation of a methylthiomethyl

ether (40) from MMB, followed by reaction of compound 40

40

streptavidin beads. Pulldown products were analyzed by
immunoblot to identify speci?c proteins. One product iden

with phosphoric acid in the presence of NCl, and then treat
ment with Na2CO3.
FIG. 11 shows synthesis of prodrugs 22-32 from FIG. 8.
Prodrugs 22-32 can be synthesized by initial treatment of
MMB with succinic anhydride in the presence of dicyclo

hexylamine (DCHA) to form hemisuccinate 41, followed by

ti?ed was IKK-B, the known target of compound 1; also the

coupling of 41 with amine 42 or 43 utilizing the EDCI-HOBt

NF-kB p65 subunit was identi?ed as a direct target in the

coupling method, and deprotection (for 22 and 23).

pull-down. Preincubation with compound 1 potently reduced
binding of IKK-B or p65 to compound 4 (lane 5), indicating

45

DETAILED DESCRIPTION OF THE
DISCLOSURE

such binding between IKK-B or p65 and compound 4 is
through the same mechanism between IKK-B or p65 and

compound 1.
FIG. 6 shows another Western blot analysis of AML cells
using compound 4, with and without treatment with com
pound 1. Primary AML cells were treated with PTL-biotin for

De?nitions
50

As used herein, the following de?nitions shall apply unless
otherwise indicated.

6 hours followed by lysis and biochemical pull-downs using
streptavidin coated agarose beads. Controls include cells
incubated with biotin alone, or preincubated with native PTL

The phrase “optionally substituted” is used interchange
55

prior to the addition of PTL-biotin. (i.e. competitive binding
studies). Lysates were analyzed by Western blot (WB) for the

have a substituent at each substitutable position of the group,
and each substitution is independent of any other. Also, com
binations of substituents or variables are permissible only if

presence of IKK or thioredoxin. (TXN). Lanes l-3 labeled

“input” represent whole cell lysates for each condition. Lanes
4-6, labeled “pull-down” are the material bound to streptavi
din beads. No pull down is observed with biotin alone (lane

such combinations result in stable compounds. In addition,
60

unless otherwise indicated, functional group radicals are

independently selected. Where “optionally substituted”

4). Both proteins are bound by PTL-biotin (lane 5). Pre

modi?es a series of groups separated by commas (e.g.,
“optionally substituted A, B or C”; or “A, B or C optionally
substituted with”), it is intended that each of the groups (e. g.,

incubation with PTL competes the PTL-biotin interaction

(lane 6).
FIG. 7 shows ef?ciency of gene transfer for primary AML

ably with the phrase “substituted or unsubstituted.” Unless
otherwise indicated, an optionally substituted group may

65

A, B and C) is optionally substituted.

specimens. Green ?uorescent protein (GFP) has been widely

The term “aliphatic” or “aliphatic group” as used herein

used as a lineage marker for mammalian cells. The use of

means a straight-chain or branched C 1_l 2 hydrocarbon chain

US 8,884,027 B2
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that is completely saturated (alkyl) or that contains one or
more units of unsaturation (alkenyl, alkynyl), or a monocyclic

and benzoisoxazolyl. The term “heteroaralkyl” refers to an

alkyl group substituted by a heteroaryl. The term “heteroary
lalkoxy” refers to an alkoxy group substituted by a heteroaryl.

C3_8 hydrocarbon or bicyclic C8_12 hydrocarbon that is com

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the

pletely saturated or that contains one or more units of unsat

uration, but which is not aromatic (also referred to herein as

5

like), heteroaryl (including heteroaralkyl, heteroarylalkoxy

“carbocycle” or “cycloalkyl”), that has a single point of

and the like), or heterocycloalkyl (including heterocycle, het

attachment to the rest of the molecule wherein any individual

erocyclyl or heterocyclic and the like) group may contain one

ring in said bicyclic ring system has 3-7 members. For

or more substituents. Suitable substituents on an unsaturated

example, suitable aliphatic groups include, but are not limited
to, linear or branched or alkyl, alkenyl, alkynyl groups and

carbon atom of an aryl, heteroaryl, aralkyl or heteroaralkyl

group are selected from halogen; haloalkyl; H; 4CF3; iR;

hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl

40R; iSR; l,2-methylenedioxy; l,2-ethylenedioxy; pro

or (cycloalkyl)alkenyl.

tected OH (such as acyloxy); phenyl (Ph); Ph substituted with

The terms “alkyl,” “alkoxy,” “hydroxyalkyl,” “alkoxy

R; iO(Ph); 4Oi(Ph) substituted with R; iCH2(Ph);
4CH2(Ph) substituted with R; iCH2CH2(Ph); 4CH2CH2
(Ph) substituted with R; iNOZ; iCN; *N(R)2; *NRC(O)
R; iNRC(O)N(R)2; *NRCOzR; *NRNRC(O)R; iNRi

alkyl” and “alkoxycarbonyl,” used alone or as part of a larger

moiety include both straight and branched chains containing
one to eighteen carbons; one to twelve carbon atoms; one to
six carbons or one to four carbons. The terms “alkenyl” and

“alkynyl” used alone or as part of a larger moiety shall include
both straight and branched chains containing two to twelve
carbon atoms.

20

The terms “haloalkyl,” “haloalkenyl” and “haloalkoxy”

NRC(O)N(R)2; *NRNRCOZR; iC(O)C(O)R; 4C(O)
CH2C(O)R; iCO2R; 4C(O)R; iC(O)N(R)2; 4OC(O)N
(Rb; *S(O)2R; *SOzN(R)2; *S(O)R; *NRSOZMRL;
*NRSOZR;
%(:S)N<R)2;
*C(:NH)*N(R)2;

i(CH2)y NHC(O)R; i(CH2)yR; i(CH2)yNHC(O)NHR;

means alkyl, alkenyl or alkoxy, as the case may be, substituted
with one or more halogen atoms. The term “halogen” or

i(CH2)yNHC(O)OR;

“halo” means F, Cl, Br or I.
The term “heteroatom” means nitrogen, oxygen, or sulfur

NHSOZR; or i(CH2)yNHC(O)CH((V)ZiR)(R) wherein
each R is independently selected from hydrogen, optionally

25

and includes any oxidized form of nitrogen and sulfur, and the
quaternized form of any basic nitrogen. Heteroatom further
includes Se, Si and P.

substituted C1_6 aliphatic, an unsubstituted 5-6 membered
4CH2(Ph)iCH2(Ph), wherein y is 0-6; Z is 0-1; andV is a
linker group. When R is C1_6 aliphatic, it may be substituted
30

with one or more substituents selected from iNH2, iNH

(C1_4 aliphatic), iN(C1_4 aliphatic)2, iS(O)(C1_4 aliphatic),
iSO2(Cl_4 aliphatic), halogen, (Cl_4 aliphatic), iOH,
40(C1_4 aliphatic), iNOZ, 4CN, iCO2H, 4C02(C1_4
aliphatic), 40(halo C1_4 aliphatic), or -halo(C1_4 aliphatic);
35

wherein each C 1_ 4 aliphatic is optionally.

An aliphatic group, including alkyl, alkenyl, alkynyl or a
non-aromatic heterocyclic ring may contain one or more sub

The term “heterocycloalkyl,” “heterocycle,” “heterocy

stituents. Suitable substituents on a saturated carbon of an

clyl” or “heterocyclic” as used herein means monocyclic,

bicyclic or tricyclic ring systems having ?ve to fourteen ring

i(CH2)y

heteroaryl or heterocyclic ring, phenyl (Ph), 40(Ph), or

The term “aryl” used alone or in combination with other

terms, refers to monocyclic, bicyclic or tricyclic carbocyclic
ring systems having a total of ?ve to fourteen ring members,
wherein at least one ring in the system is aromatic and
wherein each ring in the system contains 3 to 8 ring members.
The term “aryl” may be used interchangeably with the term
“aryl ring”. The term “aralkyl” refers to an alkyl group sub
stituted by an aryl. The term “aralkoxy” refers to an alkoxy
group substituted by an aryl.

i(CH2)yNHS(O)R;

40

aliphatic group or of a non-aromatic heterocyclic ring are
selected from those listed above for the unsaturated carbon of

members in which one or more ring members is a heteroatom,

an aryl or heteroaryl group and the following: :0, :S,

or C:O, wherein each ring in the system contains 3 to 7 ring

:NNHR, :NN(R)2, :Ni, :NNHC(O)R, :NNHCO2

members and is non-aromatic. Examples of heterocycloalkyl

(alkyl), :NNHSO2(alkyl), or :NR, where each R is inde
pendently selected from hydrogen or an optionally substi

include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tria

Zolidinyl, l,3-dioxolanyl, piperidinyl, piperaZinyl, morpholi

45

tuted C1_6 aliphatic. When R is C1_6 aliphatic, it may be

nyl, dioxanyl, hexahydropyrimidinyl; each optionally substi

substituted with one or more substituents selected from

tuted with H, C l-C6 alkyl, cycloalkyl, hydroxy, amino, halo or
tri?uoromethyl groups.

iNHz,
iNH(Cl_4 aliphatic), iN(Cl_4 aliphatic)2, halogen, iOH,
4Oi(Cl_4 aliphatic), iNOz, 4CN, 4C02H, 4C02(C1_4

The term “heteroaryl,” used alone or in combination with

other terms, refers to monocyclic, bicyclic and tricyclic ring

50

aliphatic), 40(halo C1_4 aliphatic), or -halo(C1_4 aliphatic);

systems having a total of ?ve to fourteen ring members, and
wherein: l) at least one ring in the system is aromatic; 2) at

wherein each C1_4 aliphatic is optionally substituted.

least one ring in the system contains one or more heteroatoms;

ring are selected from iR, iN(R)2, 4C(O)R, iC(O)OR,

and 3) each ring in the system contains 3 to 7 ring members.
The term “heteroaryl” may be used interchangeably with the

Substituents on a nitrogen of a non-aromatic heterocyclic

4C(O)C(O)R, 4C(O)CH2C(O)R, iSOZR, iS02N(R)2,
55

4C(:S)N(R)2,

iC(:NH)iN(R)2

or iNRSOZR;

term “heteroaryl ring” or the term “heteroaromatic”.

wherein each R is independently selected from hydrogen, an

Examples of heteroaryl rings include 2-furanyl, 3-furanyl,

optionally substituted C1_6 aliphatic, optionally substituted
phenyl (Ph), optionally substituted iO(Ph), optionally sub
stituted iCH2(Ph), optionally substituted 4CH2CH2(Ph),

2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl,
4-isoxazolyl, isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-ox
azolyl, 4-oxazolyl, 5-oxazolyl, l-pyrrolyl, 2-pyrrolyl, 3-pyr
rolyl, l-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-pyridyl, 3-py
ridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl,
3-pyridaZinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetra
zolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl,
benZimidazolyl, benzothienyl, benzofuranyl, indolyl, quino
linyl, benzotriazolyl, benzothiazolyl, benzooxazolyl, benZ
imidazolyl, isoquinolinyl, indazolyl, isoindolyl, acridinyl,

60

or an unsubstituted 5-6 membered heteroaryl or heterocyclic
ring. When R is a C 16 aliphatic group or a phenyl ring, it may
be substituted with one or more substituents selected from

iNH2, iNH(C 1_ 4 aliphatic), iN(C1_4 aliphatic)2, halogen,
65

i(Cl_4 aliphatic), 40H, iOi(Cl_4 aliphatic), iNOZ,
4CN, 4CO2H, iCOZ(Cl_4 aliphatic), 40(halo C1_4 ali
phatic) or -halo(Cl_4 aliphatic); wherein each C1_4 aliphatic is
optionally substituted.

US 8,884,027 B2
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The term “linker group” or “linker” means an organic

acid, sulfurous acid, citric acid, maleic acid, D-malic acid,
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, meth
anesulfonic acid, valeric acid, oleic acid, lauric acid, para

moiety that connects two parts of a compound. Linkers
include alkylidene chain that is a saturated or unsaturated,

straight or branched, C1_8 carbon chain which is optionally

toluenesulfonic acid, 1-naphthalensulfonic acid, 2-naphtha

substituted, and wherein up to two non-adjacent saturated
carbons of the chain are optionally replaced by R* wherein

lensulfonic acid, phthalic acid, tartaric acid, L-malic acid,
DL-malic acid, malonic acid, succinic acid, fumaric acid,

glycolic acid, thioglycolic acid, glycine, sarcocine, sulfonic
acid, nicotinic acid, picolinic acid, isonicotinic acid, benzoic
(0)4, 4S4, iSOi, iSOZi, iNRi, iSOZNRi, or

acid and substituted benzoic acid where benzene ring bears

iNRSOZi; wherein R is selected from hydrogen or option

one or more substituents.

ally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl

Pharmaceutically acceptable salts may be obtained using
standard procedures well known in the art, for example, by

or heteroaryl, and preferably H or optionally substituted C1_4
aliphatic. Optional substituents on the alkylidene chain are as
described above for an aliphatic group. Alternatively, the
linker group is R*.

reacting a suf?ciently basic compound such as an amine with
a suitable acid affording a physiologically acceptable anion.

Alkali metal (for example, sodium, potassium or lithium) or
alkaline earth metal (for example, calcium) salts of carboxy

The term “treatment” refers to any treatment of a patho

logic condition in a mammal, particularly a human, and
includes: (i) preventing the pathologic condition from occur
ring in a subject which may be predisposed to the condition
but has not yet been diagnosed with the condition and, accord
ingly, the treatment constitutes prophylactic treatment for the

disease condition; (ii) inhibiting the pathologic condition,
i.e., arresting its development; (iii) relieving the pathologic
condition, i.e., causing regression of the pathologic condi

lic acids can also be made.

The term “prodrug” or “prodrugs” is used in its ordinary
20

another moiety that is designed to be cleaved under particular

physiological conditions, leaving the deprotected or
25

tion; or (iv) relieving the conditions mediated by the patho
logic condition.
30

mammal in need of such treatment. The therapeutically effec

tive amount will vary depending upon the subject and disease
condition being treated, the weight and age of the subject, the
severity of the disease condition, the manner of administra
tion and the like, which can readily be determined by one of
ordinary skill in the art.
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acyloxy alkyl esters are described by Srivasta et al., (1984
Bioorganic Chemistry 12, 118-12), and by Freeman et al.
(1997 Progress in Medicinal Chemistry 34:112-147) which
are each incorporated in their entirety herein by reference;
and 3-phthalidyl phosphonate esters are described by Dang
Q., et al., (1999 Bioorganic & Med. Chem. Letters, 9:1505
1510), which is incorporated in its entirety herein by refer
ence. For example, and not by way of limitation, Srivasta et al.

also describe acetoxymethyl, isobutryloxymethyl, and piv
aloxymethyl as masking agents. Other suitable masking

The term “pharmaceutically acceptable salts” includes, but
is not limited to, salts well known to those skilled in the art, for

example, mono-salts (e.g. alkali metal and ammonium salts)
and poly salts (e.g. di- or tri-salts) of the compounds of the
invention. Pharmaceutically acceptable salts of compounds
of formulas (I), (11), (III), or (IV) are where, for example, an

unmasked compound of the invention. The use of masking
agents is common and well-known in the art, for example,
masking charged groups such as phosphate or phosphonate
groups. All such masking agents are suitable and can be used
with the compounds of the invention. Various agents such as

The term “therapeutically effective amount” refers to that
amount of a compound of the invention that is suf?cient to
effect treatment, as de?ned above, when administered to a

meaning in the art and means a compound of the invention
that has at least one functional moiety masked or protected by

groups comprising pivaloxyalkyl, e.g., pivaloxymethyl, or a
40

pivaloyloxy group as described by Farquhar D. et al., (1995 J.
Med. Chem., 38:488-495) which is incorporated in its entirety
herein by reference. Still other masking or protecting agents

exchangeable group, such as hydrogen in iOH, iNHi, or

are described in US. Pat. Nos. 4,816,570 and 4,968,788 both

iP(:O)(OH)i, is replaced with a pharmaceutically
acceptable cation (e.g. a sodium, potassium, or ammonium
ion) and can be conveniently be prepared from a correspond
ing compound of formula (I) by, for example, reaction with a

of which are incorporated in their entirety herein by refer

suitable base. In cases where compounds are suf?ciently
basic or acidic to form stable nontoxic acid or base salts,
administration of the compounds as salts may be appropriate.

45

ence. Lipid prodrugs are also suitable for use with the com

pounds of the invention. By non-limiting example, certain
lipid prodrugs are described in Hostetler et al., (1997 Bio
chem. Pharm. 53:1815-1822), and Hostetler et al., 1996 Anti
viral Research 31 :59-67), both of which are incorporated in
50

Examples of pharmaceutically acceptable salts are organic
acid addition salts formed with acids that form a physiologi

their entirety herein by reference. Additional examples of
suitable prodrug technology is described in WO 90/00555;

halogen, tosylate, methanesulfonate, benzenesulfonate, trif

WO 96/39831; WO 03/095665A2; US. Pat. Nos. 5,411,947;
5,463,092; 6,312,662; 6,716,825; and US. Published Patent
Application Nos. 2003/0229225 and 2003/0225277 each of
which is incorporated in their entirety herein by reference.
Such prodrugs may also possess the ability to target the drug
compound to a particular tissue within the patient, e.g., liver,
as described by Erion et al., (2004 J. Am. Chem. Soc. 126:
5154-5163; Erion et al., Am. Soc. Pharm. & Exper. Ther. DOI:
10.1124/jept.104.75903 (2004); WO 01/18013 A1; US. Pat.
No. 6,752,981), each of which is incorporated in their entirety

luoromethanesulfonate and the like; and R' is selected from

herein by reference. By way of non-limiting example, other

an optionally substituted cycloalkyl, heterocycloalkyl, aryl or

prodrugs suitable foruse with the compounds of the invention
are described in WO 03/090690; and by Harris et al., (2002
Antiviral Chem & Chemo. 12: 293-300; Knaggs et al., 2000
Bioorganic & Med. Chem. Letters 10: 2075-2078) each of
which is incorporated in their entirety herein by reference.

cal acceptable anion, for example, tosylate, methane
sulfonate, mesylate, acetate, citrate, malate, malonate, fuma
rate,
tartarate,
succinate,
benzoate,
ascorbate,
(x-ketoglutarate, and (x-glycerophosphate. Suitable inorganic
salts may also be formed, including hydrochloride, sulfate,

55

nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts include quaternary
ammonium salts formed with R'Y; where Y is selected from

60

heteroaryl.
Suitable acids include hydro?uoric acid, hydrochloric
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric
acid, phosphoric acid, carbonic acid, boric acid, selenious
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The term “drug-likeness” refers to the concept that drugs

Yoshikawa et al., 2007; Oka et al., 2007; Parada-Turska et al.,
2007; Suvannasankha et al., 2008; Wang et al., 2009; Zhang et
al., 2009). Thus, PTL not only eradicates LSC, but also bulk

share speci?c molecular properties that distinguish them
from other natural or synthetic chemicals. A drug-like mol
ecule has properties such as optimal solubility to both water
and fat, for example an orally administered drug must be
absorbed through the intestinal lining, be carried in aqueous
blood andpenetrate the lipid cellular membrane of the cell. To
be suf?ciently soluble in aqueous media such as blood and
intracellular ?uid, solubility in water can be estimated from
the number of e.g. hydrogen bond donors compared to alkyl
side-chains in the molecule. However, too many H-bond

AML cells and many other types of cancer.
Detailed SAR studies of PTL were performed to better

understand the basic chemistry required to mediate anti-leu
kemia activity. Studies indicated that the (x-methylene-y -lac
tone moiety is critical for the function of PTL, as this structure
is known to mediate Michael addition reactions (Neelakantan

donors can lead to low fat solubility, so the drug may not be

et al., 2009). In biological systems, the consequences of this
reactivity are most prevalent for free thiols and cysteine resi
dues. In addition, it was demonstrated that the epoxide ring is

able to penetrate the cell wall ef?ciently. In addition, the
drug-like molecule must be of a smaller molecular weight. A

ring resulted in at least a 10-fold reduction in anti-leukemia

also quite important for PTL activity, since loss of the epoxide

traditional method to evaluate drug-likeness is to check com

activity; molecular modeling data suggests that the epoxide

pliance with Lipinski’s Rule of Five, which covers the num

moiety may be a critical structural element in providing the
active molecular conformation of PTL. Unfortunately, PTL is

ber of hydrophilic groups, molecular weight and hydropho

bicity.
Detailed Description

20

Acute myelogenous leukemia (AML) is a life-threatening
disorder in which normal blood-formation (hematopoiesis) is
subverted by malignant transformation of normal stem or
Progenitor cells. Although an enormous amount of research

candidate to arise from these studies was dimethylaminopar

thenolide (DMAPT, LC-l, 2), which demonstrated nearly
1000-fold greater water solubility than PTL when formulated
25

as a fumarate salt. In addition, DMAPT retains virtually iden

tical anti-leukemia properties as PTL, including the ability to
selectively target LSCs. Pharmacological studies in rats and
dogs demonstrated that DMAPT is 70% orally bioavailable,

has been conducted in the area of therapeutic agents forAML,
the standard of care has not substantially changed in over 30
years. Regimens based on a combination of cytarabine (ara
C) and an anthracycline are still considered the best frontline

option for most patients, despite the relatively poor long-term
prognosis (5 year survival of approximately 20%) (Lowen

relatively water-insoluble and has poor bioavailability and
drug-likeness. A series of PTL analogs was previously pre
pared with the goal of creating a more therapeutically useful
derivative (Neelakantan et al., 2009). The most promising

30

and well tolerated at doses resulting in serum concentrations
of up to 10-fold excess of the biologically active concentra

tion (Guzman et al., 2007b). Based on these ?ndings,
DMAPT has advanced to phase 1 clinical trials, and is cur

berg et al., 1999). Thus, new options for treatment ofAML are

a high priority. Notably, clinical development of experimental

rently being evaluated in patients with advanced hematologic

therapeutics is very fast in AML, due to the poor prognosis

malignancies. DMAPT and certain PTL analogs are dis
closed in US. Pat. Nos. 7,312,242 and 7,678,904, each of

and rapid disease progression for late stage patients. There
fore, initial testing inAML not only affords the opportunity to
evaluate leukemia stem cell (LSC) targeting, but also has the

35

which is incorporated herein by reference.
Despite the characterization of DMAPT, there is still sig
ni?cant opportunity for further development of parthenolide

practical advantage of promoting rapid clinical advancement
for promising new agents.

Previously, the naturally-occurring (plant derived) com
pound parthenolide (PTL) was investigated with respect to

40

based compounds. DMAPT has a relatively short in vivo
half-life (approximately two hours) which may limit its activ

ity. Moreover, the design of this molecule does not readily

afford opportunities to develop tissue-targeting strategies due

anti-leukemia properties. PTL was found to be highly effec
tive for induction of cell death of primary human AML speci

to stability problems associated with drug formulation. This

etic cells, suggesting that non-speci?c side effects should be

is related to the ability of the drug to undergo reverse Michael
deamination reactions to generate parthenolide.
MMB (3) was identi?ed during the course of SAR studies

relatively low. Furthermore, PTL was shown to be equally

based on parthenolide (PTL, 1). In performing such studies,

mens (Guzman et al., 2005). Importantly, at comparable
doses, PTL shows little to no toxicity to normal hematopoi

45

effective amongst all subpopulations found within primary

one PTL analog that was synthesized via selenium oxide

AML specimens, including the so-called leukemia stem cell
(LSC). Studies over the past decade have strongly implicated
a relatively rare LSC population as the key driving force in
both the genesis of AML, as well as relapse following con

oxidation was a C 10 hydroxymethyl derivative. Notably,
50

concomitant conversion of the geometry of the C9 -C 1 0 double

bond from trans to cis. The resulting product, a hydroxym

ethyl 1(10)-cis-parthenolide analog, has previously been
reported as melampomagnolide B (MMB, 3). El-Feraly,

ventional therapy (Dick, 2005). Indeed, several laboratory
based studies have demonstrated that LSC are resistant to

both cytarabine and anthracyclines, and that drug regimens

55

which more effectively eradicate LSC lead to improved out

come (Costello et al., 2000; Ishikawa et al., 2007). Therefore,

and methods of treating leukemia and other cancers with
60

MMB. Unfortunately, like PTL, MMB does not possess good
drug-like properties for oral administration, as determined by
the Lipinsky’s “rule of ?ve”. Lipinski et al., Experimental and
computational approaches to estimate solubility and perme

65

Drug. Deliv. Rev. 2313-25, 1997.

for AML, PTL has demonstrated activity for virtually every
form of cancer. Indeed, the basic properties of PTL in cancer
were ?rst reported in 1973 (Wiedhopf et al., 1973), and now
appear in over 100 publications. These studies have demon

strated pre-clinical activity of PTL for cancers of the breast,

1 984.
MMB has been found to exhibit identical anti-leukemia
activity compared to PTL, as shown in FIG. 2. In one embodi

ment, the disclosure provides pharmaceutical compositions

agents that can effectively target the LSC population are of
particular interest for the treatment of AML patients.
Although one focus has been on development of treatment

hydroxylation of the C10 methyl group of PTL resulted in the

ability in drug discovery and development settings. Adv.

lung, prostate, colon, blood, liver, kidney, pancreas, brain,

MMB exhibits a C14-OH substituent, which provides

and bone (Patel et al., 2000; Sweeney et al., 2004, 2005;

opportunities for synthetic derivatization strategies. In one

